In conclusion, these findings provide novel insight into the molecular mechanism underlying ERα regulation and highlight a possible role for CHD4 as a biomarker that can benefit the development of hormone therapy for ERα-positive breast cancer. This evidence concerns the gene CHD4 and breast carcinoma.